Pharmacologic Management of Pediatric Hypertension

被引:0
|
作者
Jason Misurac
Kristen R. Nichols
Amy C. Wilson
机构
[1] Indiana University School of Medicine,Department of Pediatrics, Section of Pediatric Nephrology
[2] College of Pharmacy and Health Sciences,Department of Pharmacy Practice
[3] Butler University,Department of Pharmacy
[4] Riley Hospital for Children,undefined
[5] Indiana University Health,undefined
来源
Pediatric Drugs | 2016年 / 18卷
关键词
Chronic Kidney Disease; Aliskiren; Ambulatory Blood Pressure Monitoring; Minoxidil; Isradipine;
D O I
暂无
中图分类号
学科分类号
摘要
Hypertension in children is common, and the prevalence of primary hypertension is increasing with the obesity epidemic and changing dietary choices. Careful measurement of blood pressure is important to correctly diagnose hypertension, as many factors can lead to inaccurate blood pressure measurement. Hypertension is diagnosed based on comparison of age-, sex-, and height-based norms with the average systolic and diastolic blood pressures on three separate occasions. In the absence of hypertensive target organ damage (TOD), stage I hypertension is managed first by diet and exercise, with the addition of drug therapy if this fails. First-line treatment of stage I hypertension with TOD and stage II hypertension includes both lifestyle changes and medications. First-line agents include angiotensin-converting enzyme (ACE) inhibitors, thiazide diuretics, and calcium-channel blockers. Hypertensive emergency with end-organ effects requires immediate modest blood pressure reduction to alleviate symptoms. This is usually accomplished with IV medications. Long-term reduction in blood pressure to normal levels is accomplished gradually. Specific medication choice for outpatient hypertension management is determined by the underlying cause of hypertension and the comparative adverse effect profiles, along with practical considerations such as cost and frequency of administration. Antihypertensive medication is initiated at a starting dose and can be gradually increased to effect. If ineffective at the recommended maximum dose, an additional medication with a complementary mechanism of action can be added.
引用
收藏
页码:31 / 43
页数:12
相关论文
共 50 条
  • [1] Pharmacologic Management of Pediatric Hypertension
    Misurac, Jason
    Nichols, Kristen R.
    Wilson, Amy C.
    [J]. PEDIATRIC DRUGS, 2016, 18 (01) : 31 - 43
  • [2] Pharmacologic Treatment of Pediatric Hypertension
    Rachita S. Dhull
    Rossana Baracco
    Amrish Jain
    Tej K. Mattoo
    [J]. Current Hypertension Reports, 2016, 18
  • [3] Pharmacologic Treatment of Pediatric Hypertension
    Dhull, Rachita S.
    Baracco, Rossana
    Jain, Amrish
    Mattoo, Tej K.
    [J]. CURRENT HYPERTENSION REPORTS, 2016, 18 (04)
  • [4] Pharmacologic treatment of chronic pediatric hypertension
    Robinson R.F.
    Nahata M.C.
    Batisky D.L.
    Mahan J.D.
    [J]. Pediatric Drugs, 2005, 7 (1) : 27 - 40
  • [5] PHARMACOLOGIC MANAGEMENT OF RENOVASCULAR HYPERTENSION
    CHASSIN, MRG
    SULLIVAN, JM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1974, 227 (04): : 421 - 423
  • [6] PHARMACOLOGIC MANAGEMENT OF ADOLESCENT HYPERTENSION
    FALKNER, B
    LOWENTHAL, DT
    THANKI, B
    WASKO, D
    [J]. INTERNATIONAL JOURNAL OF PEDIATRIC NEPHROLOGY, 1983, 4 (03): : 216 - 216
  • [7] Pharmacologic Management of Portal Hypertension
    Berzigotti, Annalisa
    Bosch, Jaime
    [J]. CLINICS IN LIVER DISEASE, 2014, 18 (02) : 303 - +
  • [8] Adherence to Pharmacologic Management of Hypertension
    Ross Feldman
    Marilyn Bacher
    Norman Campbell
    Aidan Drover
    Arun Chockalingam
    [J]. Canadian Journal of Public Health, 1998, 89 : I16 - I18
  • [9] Adherence to pharmacologic management of hypertension
    Feldman, R
    Bacher, M
    Campbell, N
    Drover, A
    Chockalingam, A
    [J]. CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 1998, 89 (05): : I16 - I18
  • [10] Pharmacologic Management of Portal Hypertension
    Bunchorntavakul, Chalermrat
    Reddy, K. Rajender
    [J]. CLINICS IN LIVER DISEASE, 2019, 23 (04) : 713 - +